CSF1 and neoplasm: Using a small molecule inhibitor to the receptor of CSF-1, Priceman et al. found that the CSF-1/CSF1R pathway was necessary for the recruitment of TAMs, promoted tumor progression, and the release of proangiogenic cytokines (Priceman et al., 2010).